Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 20, 2017
Pharmacy Choice - Pharmaceutical News - Glenmark Pharmaceuticals and Evestra, Inc. Announce Partnership Agreement for Generic NuvaRing - October 20, 2017

Pharmacy News Article

 3/16/17 - Glenmark Pharmaceuticals and Evestra, Inc. Announce Partnership Agreement for Generic NuvaRing

By a News Reporter-Staff News Editor at Women's Health Weekly - Glenmark Pharmaceuticals Inc., USA, and Evestra, Inc. have completed a strategic development, license and commercialization agreement to develop and market a generic version of Merck's & Co.'s NuvaRing product - etonogestrel/ethinyl estradiol vaginal ring - designed to allow women access to a more affordable birth control option (see also Glenmark Pharmaceuticals).

Development on the vaginal ring product is currently under way and the two companies expect to file an Abbreviated New Drug Application (ANDA) in fiscal 2019.

Evestra will develop this product exclusively for Glenmark for the U.S. market, and will receive certain milestone payments during various stages of the product's development, including royalties on net sales.

"This is an important U.S.-based strategic partnership for Evestra," said President and CEO Ze'ev Shaked. "By aligning our efforts, we expect to make great strides in improving women's healthcare and access to options that are significantly more accessible due to their lower costs. We are excited to work with Glenmark."

Glenmark has secured exclusive marketing and distribution rights for the product, including an option to commercialize two additional Evestra vaginal ring products, for the U.S. market.

"Bringing high-quality and affordable options to market has been a core commitment for Glenmark since the beginning," said Robert Matsuk, President - North America and Global API, Glenmark Pharmaceuticals Ltd. "The partnership with Evestra underscores that focus, and expands our portfolio into a leading non-daily contraceptive option prescribed to millions of women in the U.S."

Merck's IMS Health NuvaRing registered sales of $768 million in 2016 in the U.S. market.

NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.

Keywords for this news article include: Glenmark Pharmaceuticals, Gynecology, Women's Health, Gonadal Hormones, Estradiol Congeners, Marketing and Licensing Agreements.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement